ErlySign funding, investors and company details

ErlySign is an emerging Healthcare startup from Nagpur, working in the space of Healthtech startup focused on early detection of oral cancer through saliva-based diagnostic kits.. Founded by Shubhendra Singh Thakur, Deovrat Begde.

Company: CURO Biosciences Private Limited
Sector: Healthcare
Location: Nagpur
Founders: Shubhendra Singh Thakur, Deovrat Begde
Total funding raised: ₹16 Cr

Company overview

ErlySign is a healthtech startup founded in 2019, focused on early detection of oral cancer through saliva-based diagnostic kits. The company has developed a non-invasive, affordable, and accurate solution that allows individuals to test for pre-cancerous conditions from the comfort of their homes. Using a simple saliva collection kit, biomarkers are analyzed to assess risk levels categorized as low, moderate, or high, even before visible lesions or tumors appear. ErlySign’s flagship product, the Oral Cancer Detection Kit, delivers results in just 15 minutes with clinically tested precision of up to 98% accuracy, making it significantly more cost-effective than traditional biopsy methods. ErlySign is driven by innovation in life sciences, deeptech, and medtech, aiming to make cancer detection painless, accessible, and affordable for millions.

Funding rounds

Latest round (Pre Series A): ₹16.00 Cr. ($ 1.85 Mn), 2025-01-16. Investors: Ashish Kacholia